Deprivation of arginine by recombinant human arginase in prostate cancer cells
Journal of Hematology & Oncology, 05/01/2012Hsueh EC et al.
Recombinant human arginase (rhArg) causes significant cytotoxicity in LNCaP, DU–145 and PC–3 prostate cancer cells which all demonstrate decreased ornithine carbamoyl transferase (OCT) expression. Inhibition of mTOR manifested by hypophosphorylation of 4E–BP1 suggests autophagy is involved as alternative cell death mechanism. rhArg demonstrates a promising novel agent for prostate cancer treatment.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.